LGND stock forecast
Our latest prediction for Ligand Pharmaceuticals, Inc.'s stock price was made on the Sept. 3, 2019 when the stock price was at 87.17$.
In the short term (2weeks), LGND's stock price should outperform the market by 1.55%. During that period the price should oscillate between -4.77% and +6.59%.
In the medium term (3months), LGND's stock price should outperform the market by 1.35%. During that period the price should oscillate between -12.58% and +16.57%.Get email alerts
About Ligand Pharmaceuticals, Inc.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
At the moment the company generates 174M USD in revenues.
On its last earning announcement, the company reported a profit of 32.49$ per share.
The book value per share is 29.37$
Three months stock forecastSept. 3, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|